New Releases from NCBI BookshelfTarlatamab (Imdelltra): Indication: The treatment of adult patients with extensive-stage small cell lung cancer with disease progression on or after at least 2 prior lines of therapy including platinum-based chemotherapy: Reimbursement Recommendation [Internet].​Tarlatamab (Imdelltra): Indication: The treatment of adult patients with extensive-stage small cell lung cancer with disease progression on or after at least 2 prior lines of therapy including platinum-based chemotherapy: Reimbursement Recommendation [Internet].

Canada’s Drug Agency (CDA-AMC) recommends that Imdelltra be reimbursed by public drug plans for the treatment of extensive-stage small cell lung cancer (ES-SCLC) in patients with disease progression on or after at least 2 prior lines of therapy including platinum-based chemotherapy if certain conditions are met.

​ 

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top